Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Modern Pathology

• Publication date

  2018-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41379-018-0030-xPMID 29463884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  2017cited by this paper
• Breast cancer genomics and immuno-oncological markers to guide immune therapies.

  2017cited by this paper
• Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features

  2017cited by this paper
• Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

  2017cited by this paper
• Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Elements of cancer immunity and the cancer–immune set point

  2017cited by this paper
• Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ

  2017cited by this paper
• Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

  2017cited by this paper
• Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

  2017cited by this paper
• Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade

  2016cited by this paper
• CD8+ tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ

  2016cited by this paper
• Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study

  2016cited by this paper
• Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast

  2016cited by this paper
• The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ

  2016cited by this paper
• The genomic landscape of breast cancer and its interaction with host immunity.

  2016cited by this paper
• The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

  2016cited by this paper
• Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial

  2016cited by this paper
• Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication

  2016cited by this paper
• An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.

  2016cited by this paper
• The immune microenvironment of breast ductal carcinoma in situ

  2016cited by this paper
• The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis

  2016cited by this paper
• Clinical significance of tumor-infiltrating lymphocytes in breast cancer

  2016cited by this paper
• Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

  2016cited by this paper
• Murine Butyrophilin-Like 1 and Btnl6 Form Heteromeric Complexes in Small Intestinal Epithelial Cells and Promote Proliferation of Local T Lymphocytes

  2016cited by this paper
• Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention

  2016cited by this paper
• Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients

  2015cited by this paper
• A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.

  2015cited by this paper
• Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer

  2015cited by this paper
• Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study

  2015cited by this paper
• Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy

  2015cited by this paper
• Relevance of tumor-infiltrating lymphocytes in breast cancer

  2015cited by this paper
• Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

  2015cited by this paper
• The role of inflammation in progression of breast cancer: Friend or foe? (Review).

  2015cited by this paper
• Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score

  2015cited by this paper
• Human breast cancer cells educate macrophages toward the M2 activation status

  2015cited by this paper
• Classical pathology and mutational load of breast cancer – integration of two worlds

  2015cited by this paper
• Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance.

  2015cited by this paper
• Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

  2015cited by this paper
• Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

  2015cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• Tertiary lymphoid structures in cancer and beyond.

  2014cited by this paper
• Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

  2014cited by this paper
• Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

  2013cited by this paper
• Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

  2013cited by this paper
• CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.

  2013cited by this paper
• Myeloid-derived suppressor cells in breast cancer

  2013cited by this paper
• Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

  2013cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• New Insights into the Role of the Immune Microenvironment in Breast Carcinoma

  2013cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

  2013cited by this paper
• FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer

  2012cited by this paper
• The prognostic significance of B lymphocytes in invasive carcinoma of the breast

  2012cited by this paper
• Carcinoma origin dictates differential skewing of monocyte function

  2012cited by this paper
• Ductal carcinoma in situ: current morphological and molecular subtypes

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature

  2012cited by this paper
• Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients

  2012cited by this paper
• Effect of three decades of screening mammography on breast-cancer incidence.

  2012cited by this paper
• HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

  2012cited by this paper
• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer

  2012cited by this paper
• CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

  2012cited by this paper
• Ductal Carcinoma in Situ (DCIS) of the breast

  2012cited by this paper
• The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer.

  2012cited by this paper
• An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome

  2011cited by this paper
• Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade

  2011cited by this paper
• CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes

  2011cited by this paper
• Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.

  2011cited by this paper
• Ductal carcinoma in situ: risk factors and impact of screening.

  2010cited by this paper
• Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease

  2010cited by this paper
• Macrophage diversity enhances tumor progression and metastasis.

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Immune infiltration in human tumors: a prognostic factor that should not be ignored

  2010cited by this paper
• Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ

  2010cited by this paper
• Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer

  2009cited by this paper
• T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

  2009cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009cited by this paper
• Characterization of High-grade Ductal Carcinoma In Situ With and Without Regressive Changes: Diagnostic and Biologic Implications

  2009cited by this paper
• Tumour-infiltrating CD4 and CD8 T lymphocytes in breast cancer

  2008cited by this paper
• Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast

  2008cited by this paper
• The humoral immune system has a key prognostic impact in node-negative breast cancer.

  2008cited by this paper
• Development of vaccines for high-risk ductal carcinoma in situ of the breast.

  2007cited by this paper
• Identification of a basal-like subtype of breast ductal carcinoma in situ.

  2007cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations

  2006cited by this paper
• Different patterns of inflammation and prognosis in invasive carcinoma of the breast

  2006cited by this paper
• The natural history of low‐grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long‐term follow‐up

  2005cited by this paper
• Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy

  2005cited by this paper
• Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.

  2004cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper

• Active Surveillance of Ductal Carcinoma In-Situ

  2026cites this paper
• The benefits of Lactiplantibacillus plantarum: from immunomodulator to vaccine vector.

  2025cites this paper
• Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches

  2025cites this paper
• B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses

  2025cites this paper
• Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study

  2024cites this paper
• Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package

  2024cites this paper
• Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types

  2024cites this paper
• Areca nut extract increased stromal tumor-infiltrating lymphocytes in 4-nitroquinoline-1-oxide-tumor-induced Sprague-Dawley rats

  2024cites this paper
• Advances in research on immune escape mechanism of glioma

  2023cites this paper
• signifinder enables the identification of tumor cell states and cancer expression signatures in bulk, single-cell and spatial transcriptomic data

  2023cites this paper
• Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

  2022cites this paper
• The role of IL-35 and IL-37 in breast cancer – potential therapeutic targets for precision medicine

  2022cites this paper
• Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ

  2022cites this paper
• NR3C2-Related Transcriptome Profile and Clinical Outcome in Invasive Breast Carcinoma

  2021cites this paper
• Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ

  2021cites this paper
• Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection

  2021cites this paper
• Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells

  2021cites this paper
• Relationship between Th17 immune response and cancer

  2021cites this paper
• A Review of the Recent Findings on Ductal Carcinoma In Situ of the Breast (DCIS)

  2020cites this paper
• Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent

  2020cites this paper
• Deep-Learning–Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data

  2020cites this paper
• Tumour‐infiltrating lymphocytes in ductal carcinoma in situ (DCIS)—assessment with three different methodologies and correlation with Oncotype DX DCIS Score

  2020cites this paper
• Interobserver Variability in Ductal Carcinoma In Situ of the Breast.

  2020cites this paper
• Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes : relationship with Th 17 cytokine profile

  2019cites this paper
• Ductal carcinoma in situ of the breast: immune cell composition according to subtype

  2019cites this paper
• Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS)

  2019cites this paper
• Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance

  2019cites this paper
• Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile

  2019cites this paper
• A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast

  2019cites this paper
• Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ.

  2019cites this paper
• Protein profiling of fine‐needle aspirates reveals subtype‐associated immune signatures and involvement of chemokines in breast cancer

  2019cites this paper
• Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.

  2019cites this paper
• Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

  2019influential citation
• Higher densities of tumour‐infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast

  2019cites this paper
• DCIS of the breast : aspects on treatment and prognosis

  2018cites this paper